<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459263</url>
  </required_header>
  <id_info>
    <org_study_id>NL26327.091.09</org_study_id>
    <nct_id>NCT01459263</nct_id>
  </id_info>
  <brief_title>Early Outcome of Mechanochemical Endovenous Ablation</brief_title>
  <acronym>ClariVein-2</acronym>
  <official_title>Mechanochemical Endovenous Ablation of Great Saphenous Vein Incompetence Using the ClariVeinTM Device: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than 25 percent of the general population suffers from varicose veins, which has a
      considerable impact on quality of life. Nowadays endovenous treatment modalities for great
      saphenous incompetence are widely accepted. Mechanochemical endovenous ablation is a new
      tumescent-less technique, that combines mechanical endothelial damage using a rotating wire
      with the infusion of a liquid sclerosant. The current study aims at evaluating short and long
      term outcome after mechanochemical endovenous ablation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occlusion rate</measure>
    <time_frame>30 days, 1, 2, and 5 years</time_frame>
    <description>The percentage of GSV occluded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health status</measure>
    <time_frame>30 days, 1, 2, and 5 years</time_frame>
    <description>Using the RAND 36-Item Short Form Health Survey (SF-36)the general health status will be evaluated at the mentioned time points.
The SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease related quality of life</measure>
    <time_frame>30 days, 1, 2, and 5 years</time_frame>
    <description>Using the AVVQ (Aberdeen Varicose Vein questionnaire) the quality of life related to the disease will be evaluated at the mentioned time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score during procedure</measure>
    <time_frame>peri-procedural</time_frame>
    <description>The pain will be scored during procedure using the VAS score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-weeks post-procedure pain score</measure>
    <time_frame>two weeks</time_frame>
    <description>The pain will be scored daily for two weeks after the procedure using the VAS score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recovery time</measure>
    <time_frame>two weeks</time_frame>
    <description>The time (in days) after the procedure until patients were able to restart daily activity/daily work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedural complications</measure>
    <time_frame>during procedure</time_frame>
    <description>all complications related to the procedure will be evaluated at the mentioned time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-procedural complications</measure>
    <time_frame>1 year</time_frame>
    <description>all complications related to the procedure will be evaluated at the mentioned time points.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">124</enrollment>
  <condition>Varicosis</condition>
  <arm_group>
    <arm_group_label>GSV insufficiency</arm_group_label>
    <description>Patients with insufficiency of the greater saphenous vein (GSV) will be included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClariVein</intervention_name>
    <description>Using the ClariVein device, the GSV will be occluded.</description>
    <arm_group_label>GSV insufficiency</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with insufficiency of the greater saphenous vein will be included.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Insufficiency of the GSV

          -  Ultrasound criteria for endovenous treatment have been met:

          -  Diameter GSV between 3-12 mm

          -  No thrombus present at the GSV part to be treated

          -  Signed informed consent

          -  Patient willing to present at follow-up visits

          -  Age &gt; 18 jaar

        Exclusion Criteria:

          -  Patient is unable to give informed consent

          -  Patient unable to present at all follow-up visits

          -  Other treatment is more suitable for the treatment of the varicose veins than
             mechano-chemical ablation

          -  Pregnancy and breast feeding

          -  Known allergy/ contra indication for sclerotherapy

          -  Previous ipsilateral surgical treatment of varicose veins

          -  Deep venous vein thrombosis in medical history

          -  Anticoagulant therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel MJ Reijnen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rijnstate Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Paul Vries, de, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>van Eekeren RR, Boersma D, Elias S, Holewijn S, Werson DA, de Vries JP, Reijnen MM. Endovenous mechanochemical ablation of great saphenous vein incompetence using the ClariVein device: a safety study. J Endovasc Ther. 2011 Jun;18(3):328-34. doi: 10.1583/11-3394.1.</citation>
    <PMID>21679070</PMID>
  </results_reference>
  <results_reference>
    <citation>van Eekeren RR, Boersma D, de Vries JP, Reijnen MM. [Endovenous mechanochemical ablation for varicose veins--a new endovenous technique without tumescent anaesthesia]. Ned Tijdschr Geneeskd. 2011;155(33):A3177. Dutch.</citation>
    <PMID>21854655</PMID>
  </results_reference>
  <results_reference>
    <citation>van Eekeren RR, Boersma D, Konijn V, de Vries JP, Reijnen MM. Postoperative pain and early quality of life after radiofrequency ablation and mechanochemical endovenous ablation of incompetent great saphenous veins. J Vasc Surg. 2013 Feb;57(2):445-50. doi: 10.1016/j.jvs.2012.07.049. Epub 2012 Nov 8.</citation>
    <PMID>23141679</PMID>
  </results_reference>
  <results_reference>
    <citation>Boersma D, van Eekeren RR, Werson DA, van der Waal RI, Reijnen MM, de Vries JP. Mechanochemical endovenous ablation of small saphenous vein insufficiency using the ClariVein(Â®) device: one-year results of a prospective series. Eur J Vasc Endovasc Surg. 2013 Mar;45(3):299-303. doi: 10.1016/j.ejvs.2012.12.004. Epub 2013 Jan 9.</citation>
    <PMID>23312507</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rijnstate Hospital</investigator_affiliation>
    <investigator_full_name>Michel Reijnen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>GSV</keyword>
  <keyword>insufficiency</keyword>
  <keyword>ClariVein device</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <keyword>QOL</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

